Interim Results from the IMPACT Study : Evidence for Prostate-specific Antigen Screening in BRCA2 Mutation Carriers
Page, Elizabeth C. (Institute of Cancer Research)
Bancroft, Elizabeth (The Royal Marsden NHS Foundation Trust)
Brook, Mark N. (Institute of Cancer Research)
Assel, Melissa (Memorial Sloan Kettering Cancer Center)
Hassan Al Battat, Mona (Lund University)
Thomas, Sarah (The Royal Marsden NHS Foundation Trust)
Taylor, Natalie (The Royal Marsden NHS Foundation Trust)
Chamberlain, Anthony (Institute of Cancer Research)
Pope, Jennifer (Institute of Cancer Research)
Raghallaigh, Holly Ni (Institute of Cancer Research)
Evans, Gareth (Central Manchester University Hospitals NHS Foundation Trust)
Rothwell, Jeanette (Central Manchester University Hospitals NHS Foundation Trust)
Maehle, Lovise (Oslo University Hospital (Oslo, Noruega))
Grindedal, Eli Marie (Oslo University Hospital (Oslo, Noruega))
James, Paul (The Royal Melbourne Hospital)
Mascarenhas, Lyon (Peter MacCallum Cancer Centre)
McKinley, Joanne (Peter MacCallum Cancer Centre)
Side, Lucy (Princess Anne Hospital)
Thomas, Tessy (Princess Anne Hospital)
van Asperen, Christi (Leiden University Medical Center)
Vasen, Hans (The Foundation for the Detection of Hereditary Cancer)
Kiemeney, Lambertus A. (Radboud University Medical Center)
Ringelberg, Janneke (The Foundation for the Detection of Hereditary Cancer)
Jensen, Thomas Dyrso (Vejle Hospital (Vejle, Dinamarca))
Osther, Palle Jörn Sloth (Vejle Hospital (Vejle, Dinamarca))
Helfand, Brian T. (NorthShore University HealthSystem)
Genova, Elena (NorthShore University HealthSystem)
Oldenburg, Rogier A. (Erasmus University Medical Center)
Cybulski, Cezary (Pomeranian Medical University in Szczecin)
Wokolorczyk, Dominika (Pomeranian Medical University in Szczecin)
Ong, Kai-Ren (Birmingham Women's Hospital)
Huber, Camilla (Birmingham Women's Hospital)
Lam, Jimmy (Bedford Park)
Taylor, Louise (Daw Park)
Salinas, Monica (Hospital Universitari de Bellvitge)
Feliubadaló, Lidia (Hospital Universitari de Bellvitge)
Oosterwijk, Jan C. (University of Groningen)
van Zelst-Stams, Wendy (Radboud University Medical Center)
Cook, Jackie (Sheffield Children's Hospital (Sheffield, Regne Unit))
Rosario, Derek J. (Royal Hallamshire Hospital)
Domchek, Susan M. (Basser Research Center. University of Pennsylvania)
Powers, Jacquelyn (University of Pennsylvania)
Buys, Saundra (University of Utah)
O'Toole, Karen (University of Utah)
Ausems, Margreet G. E. M. (University Medical Centre)
Schmutzler, Rita K. (Uniklinik Köln (Colònia, Alemanya))
Rhiem, Kerstin (Uniklinik Köln (Colònia, Alemanya))
Izatt, Louise (Guy's and St Thomas' NHS Foundation Trust)
Tripathi, Vishakha (Guy's and St Thomas' NHS Foundation Trust)
Teixeira, Manuel R. (Universidade do Porto)
Cardoso, Marta (Portuguese Oncology Institute (IPO Porto))
Foulkes, William (McGill University, Departments of Human Genetics and Oncology)
Aprikian, Armen (Research Institute of McGill University Health Centre)
van Randeraad, Heleen (The Foundation for the Detection of Hereditary Cancer)
Davidson, Rosemarie (Queen Elizabeth University Hospital, Glasgow)
Longmuir, Mark (Queen Elizabeth University Hospital, Glasgow)
Ruijs, Marielle W.G. (The Netherlands Cancer Institute (Amsterdam, Països Baixos))
Helderman van den Enden, Apollonia T.J.M. (Maastricht UMC)
Adank, Muriel A. (Amsterdam UMC)
Williams, Rachel (Prince of Wales Hospital (Australia))
Andrews, Lesley (Prince of Wales Hospital (Australia))
Murphy, Declan G. (Peter MacCallum Cancer Centre)
Halliday, Dorothy (Oxford Centre for Genomic Medicine)
Walker, Lisa (Oxford Centre for Genomic Medicine)
Liljegren, Annelie (Karolinska University Hospital and Karolinska Institutet (Suècia))
Carlsson, Stefan (Karolinska University Hospital and Karolinska Institutet (Suècia))
Azzabi, Ashraf (Newcastle Upon Tyne Hospitals NHS Trust (Newcastle, Regne Unit))
Jobson, Irene (Newcastle Upon Tyne Hospitals NHS Trust (Newcastle, Regne Unit))
Morton, Catherine (The Royal Melbourne Hospital)
Shackleton, Kylie (The Royal Melbourne Hospital)
Snape, Katie (St George's University Hospitals NHS Foundation Trust)
Hanson, Helen (St George's University Hospitals NHS Foundation Trust)
Harris, Marion (Monash Health)
Tischkowitz, Marc (University of Cambridge)
Taylor, Amy (Cambridge University Hospitals NHS Foundation Trust (Anglaterra))
Kirk, Judy (Sydney Medical School)
Susman, Rachel (Royal Brisbane & Women's Hospital)
Chen-Shtoyerman, Rakefet (Kaplan Medical Center)
Spigelman, Allan (The Kinghorn Cancer Centre. St Vincent's Hospital)
Pachter, Nicholas (University of Western Australia)
Ahmed, Munaza (NE Thames Regional Genetics Service)
Ramon y Cajal, Teresa (Institut d'Investigació Biomèdica Sant Pau)
Zgajnar, Janez (Institute of Oncology)
Brewer, Carole (Royal Devon and Exeter Hospital)
Gadea, Neus (Hospital Universitari Vall d'Hebron)
Brady, Angela F. (London North West University Healthcare NHS Trust)
Van Os, Theo (Universiteit van Amsterdam. Akademisch Medisch Centrum)
Gallagher, David (St James's Hospital)
Johannsson, Oskar (Landspitali University Hospital (Reykjavík, Islàndia))
Donaldson, Alan (St Michael's Hospital)
Barwell, Julian (University Hospitals Leicester)
Nicolai, Nicola (Istituto Nazionale dei Tumori (Milà, Itàlia))
Friedman, Eitan (Chaim Shema Medical Center)
Obeid, Elias (Fox Chase Cancer Center)
Greenhalgh, Lynn (Liverpool Women's Hospital)
Murthy, Vedang (Tata Memorial Centre)
Copakova, Lucia (National Cancer Institute)
Saya, Sibel (Institute of Cancer Research)
McGrath, John (University of Exeter Medical School)
Cooke, Peter (New Cross Hospital)
Rønlund, Karina (Vejle Hospital (Vejle, Dinamarca))
Richardson, Kate (Peter MacCallum Cancer Centre)
Henderson, Alex (West Cumberland Infirmary)
Teo, Soo (Subang Jaya Medical Centre)
Arun, Banu K. (The University of Texas)
Kast, Karin (Technische Universität Dresden)
Dias, Alexander (Instituto Nacional de Cancer Jose de Alencar Gomes da Silva (INCA))
Aaronson, Neil K. (The Netherlands Cancer Institute (Amsterdam, Països Baixos))
Ardern-Jones, Audrey (The Royal Marsden NHS Foundation Trust)
Bangma, Chris H. (Erasmus University Medical Center)
Castro, Elena (Centro Nacional de Investigaciones Oncológicas)
Dearnaley, David (The Institute of Cancer Research. Royal Marsden NHS Foundation Trust (Londres, Regne Unit))
Eccles, Diana M. (The University of Southampton Medical School)
Tricker, Karen (Central Manchester University Hospitals NHS Foundation Trust)
Eyfjord, Jorunn (University of Iceland)
Falconer, Alison (Imperial College Healthcare National Health Service Trust (Londres, Regne Unit))
Foster, Christopher (HCA Pathology Laboratories)
Gronberg, Henrik (University Hospital)
Hamdy, Freddie C. (University of Oxford)
Stefansdottir, Vigdis (Landspitali University Hospital (Reykjavík, Islàndia))
Khoo, Vincent (University of Melbourne)
Lindeman, Geoffrey J. (The Walter and Eliza Hall Institute of Medical Research)
Lubinski, Jan (Pomeranian Medical University in Szczecin)
Axcrona, Karol (Akershus University Hospital)
Mikropoulos, Christos (Medway Hospital)
Mitra, Anita (University College London Hospitals NHS Foundation Trust)
Moynihan, Clare (Institute of Cancer Research)
Rennert, Gad (Carmel Medical Center)
Suri, Mohnish (Nottingham City Hospital)
Wilson, Penny (Innovate UK. Polaris House)
Dudderidge, Tim (University Hospital Southampton)
Offman, Judith (King's College London)
Kote-Jarai, Zsofia (Institute of Cancer Research)
Vickers, Andrew J. (Memorial Sloan Kettering Cancer Center)
Lilja, Hans (Memorial Sloan Kettering Cancer Center)
Eeles, Rosalind (The Royal Marsden NHS Foundation Trust)
Universitat Autònoma de Barcelona

Date:	2019
Abstract:	Mutations in BRCA2 cause a higher risk of early-onset aggressive prostate cancer (PrCa). The IMPACT study is evaluating targeted PrCa screening using prostate-specific-antigen (PSA) in men with germline BRCA1/2 mutations. To report the utility of PSA screening, PrCa incidence, positive predictive value of PSA, biopsy, and tumour characteristics after 3 yr of screening, by BRCA status. Men aged 40-69 yr with a germline pathogenic BRCA1/2 mutation and male controls testing negative for a familial BRCA1/2 mutation were recruited. Participants underwent PSA screening for 3 yr, and if PSA.
Grants:	Ministerio de Economía y Competitividad PI13/00285 Ministerio de Economía y Competitividad PIE13/00022 Ministerio de Economía y Competitividad PI16/00563
Rights:	Aquest document està subjecte a una llicència d'ús Creative Commons. Es permet la reproducció total o parcial, la distribució, i la comunicació pública de l'obra, sempre que no sigui amb finalitats comercials, i sempre que es reconegui l'autoria de l'obra original. No es permet la creació d'obres derivades.
Language:	Anglès
Document:	Article ; recerca ; Versió publicada
Subject:	BRCA1 ; BRCA2 ; Prostate-specific-antigen ; Prostate cancer ; Targeted prostate screening
Published in:	European Urology, Vol. 76 Núm. 6 (december 2019) , p. 831-842, ISSN 1873-7560

DOI: 10.1016/j.eururo.2019.08.019
PMID: 31537406

12 p, 2.4 MB

The record appears in these collections:
Research literature > UAB research groups literature > Research Centres and Groups (research output) > Health sciences and biosciences > Institut de Recerca Sant Pau
Articles > Research articles
Articles > Published articles